HOXC11 promotes head and neck squamous cell carcinomas (HNSCC) progression by regulating SPHK1 through the Wnt signaling pathway

Cancer Gene Therapy · Published 2026-07-25 · DOI 10.1038/s41417-026-01062-3

Authors (4)

Jing Zhang, Qionghui Wu, Jingyuan Liu, Shisheng Li

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Zhang, J., Wu, Q., Liu, J., et al. (2026). HOXC11 promotes head and neck squamous cell carcinomas (HNSCC) progression by regulating SPHK1 through the Wnt signaling pathway. Cancer Gene Therapy. https://doi.org/10.1038/s41417-026-01062-3

Related articles

• The role of STAT3 in regulating ferroptosis in cancer: molecular mechanisms and targeted therapeutic perspectives · Cancer Gene Therapy · 2026 · Same journal
• b-AP15 enhances TRAIL-induced cell death in HNSCC via the induction of ROS/JNK/DR5 signalling · Cancer Gene Therapy · 2026 · Same journal
• COL3A1 promotes gastric cancer progression by activating PI3K/AKT signaling · Cancer Gene Therapy · 2026 · Same journal
• Inhibiting CXCL12/CXCR4 axis enhances T cell activity in gastric cancer · Cancer Gene Therapy · 2026 · Same journal
• Memory programming and new manufacturing paradigms in CAR-T cell therapy · Cancer Gene Therapy · 2026 · Same journal
• Dioscin suppresses tumorigenesis and overcomes radioresistance by promoting ubiquitination-mediated degradation of Mcl-1 · Cancer Gene Therapy · 2026 · Same journal
• SPARC family proteins: matricellular modulators of cancer progression and therapeutic resistance · Cancer Gene Therapy · 2026 · Same journal
• The Tumor-suppressive role of CNTNAP2 in glioma: Dual regulation of the NDN-ERK axis and M2 macrophage polarization · Cancer Gene Therapy · 2026 · Same journal
• Reprogramming the tumor microenvironment via TFF3 targeting: a potential novel avenue to boost CAR-T cell therapy in solid tumors · Cancer Gene Therapy · 2026 · Same journal
• LMTK3 regulates breast cancer angiogenesis via a context-dependent mesenchymal-epithelial transition program · Cancer Gene Therapy · 2026 · Same journal